<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851301</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00095888</org_study_id>
    <nct_id>NCT04851301</nct_id>
  </id_info>
  <brief_title>Neural Mechanisms of Immersive Virtual Reality in Chronic Pain</brief_title>
  <official_title>Neural Mechanisms of Immersive Virtual Reality in Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project examines, in chronic pain, the mechanisms of immersive virtual reality compared&#xD;
      to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological&#xD;
      premises for low-risk interventions for pain management is high.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Virtual reality (VR) has been seen as an intervention for alleviating clinical chronic (and&#xD;
      acute) pain. An approach to pain management utilizing VR presents opportunities for reducing&#xD;
      pain and suffering by using immersive, aesthetic, and multisensory stimulation. Investigator&#xD;
      will analyze the behavioral and neural mechanisms of active VR against sham VR as two methods&#xD;
      that investigate descending pain modulation. Thus, the central hypothesis is that those who&#xD;
      respond to placebos will likely respond to active VR. If VR-induced analgesia depends upon&#xD;
      the release of endogenous opioids.&#xD;
&#xD;
      In this project, the investigators will determine the effects of VR at the neural and&#xD;
      clinical levels directly for TMD participants, inviting participants from an existing Colloca&#xD;
      Lab-based cohort phenotyped for diagnosis, grade, and low/high impact pain profiles and&#xD;
      prospective TMD participants in collaboration with Johns Hopkins University. These&#xD;
      participants have agreed to be recontacted for further research. Investigator will determine&#xD;
      the role of the opioid tone (AIM1). In Aim 1, the investigators will determine the role of&#xD;
      the endogenous opioid tone for VR-induced hypoalgesia in TMD participants using VR, tonic&#xD;
      painful stimuli, and naloxone given intranasally with established mu-opioid receptor&#xD;
      occupancy to determine how the opioid tone shapes VR-induced hypoalgesia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2027</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>AIM 1: This is a double-blinded, randomized, between- and within-subjects design (3 X 3) with TMD participants randomly assigned to one of three groups. The three groups are 1. Naloxone group 2. Saline group 3. Natural history group, in which participants will not be given any drugs. Within-subjects factor: All three groups will go through the following 3 conditions:1. Active VR (theBlu); 2. Sham VR; 3. No-VR.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The UM Pharmacy will assign de-identified study IDs to participants and provide the study drug (Naloxone or Saline) so that participants, the person conducting the experiment, and the investigator will be blind to the participant's group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemic pain endurance</measure>
    <time_frame>one session lasting from 2 to 3 hours</time_frame>
    <description>Increments in experimental ischemic pain endurance will be assessed using a timer (minutes of tolerance)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic pain rating</measure>
    <time_frame>one session lasting from 2 to 3 hours</time_frame>
    <description>Increments in experimental ischemic pain endurance will be assessed using Visual Analogue Scale (VAS) (self-reported numbers) anchored from 0=no pain to 100=maximum tolerable pain. The VAS will be used every 10 seconds during the ischemic pain endurance task</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">259</enrollment>
  <condition>Pain</condition>
  <condition>Virtual Reality</condition>
  <condition>Placebo</condition>
  <condition>Temporomandibular Disorder</condition>
  <arm_group>
    <arm_group_label>Naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NARCANÂ® Naloxone Nasal Spray will be used to determine how the opioid tone shapes VR-induced hypoalgesia. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Saline group, where participants will be given saline solution (4mg) via an identical spray device. Participants will be stratified for sex and then randomized to saline arm (The dose of saline will be (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natural History</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Natural history group, where participants will not be given any drugs. Participants will be stratified for sex and then randomized to the Natural History group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Active Virtual Reality</intervention_name>
    <description>Participants will be assigned to an immersive VR environment.</description>
    <arm_group_label>Naloxone</arm_group_label>
    <arm_group_label>Natural History</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Active VR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>sham Virtual Reality</intervention_name>
    <description>Participants will be assigned to a sham VR environment without the immersive experience.</description>
    <arm_group_label>Naloxone</arm_group_label>
    <arm_group_label>Natural History</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Sham VR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>Participants will experience tonic pain tolerance tests without exposure to any environments.</description>
    <arm_group_label>Naloxone</arm_group_label>
    <arm_group_label>Natural History</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).&#xD;
A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.</description>
    <arm_group_label>Naloxone</arm_group_label>
    <other_name>Naloxone Hydrochloride/Narcan Intranasal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.&#xD;
A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo, Sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natural history</intervention_name>
    <description>Participants will not be provided Naloxone or Saline.</description>
    <arm_group_label>Natural History</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age (18-88 years)&#xD;
&#xD;
          -  English speaker (written and spoken)&#xD;
&#xD;
          -  Temporal Mandibular Disorder (TMD) for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Present or past degenerative neuromuscular disease&#xD;
&#xD;
          -  Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver&#xD;
             disease, history of cancer within past 3 years&#xD;
&#xD;
          -  Cervical pain other than TMD related (e.g. stenosis, radiculopathy)&#xD;
&#xD;
          -  Any personal (or family first degree) history of mania, schizophrenia, or other&#xD;
             psychoses&#xD;
&#xD;
          -  Severe psychiatric condition (e.g., schizophrenia, bipolar disorders, autism) leading&#xD;
             to hospitalization within the last 3 years.&#xD;
&#xD;
          -  Use of antidepressants, ADHD medication, non-over-the-counter painkillers, methadone,&#xD;
             benzodiazepines, barbiturates, and/or narcotics during the past 3 months&#xD;
&#xD;
          -  Lifetime alcohol/drug dependence or alcohol/drug abuse in the past 3 months&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Color-blindness&#xD;
&#xD;
          -  Pain in jaw or temple in last 3 months due to toothache or infection&#xD;
&#xD;
          -  Any facial trauma that has occurred in the last 6 weeks&#xD;
&#xD;
          -  History of severe facial trauma in the last 3 months&#xD;
&#xD;
          -  Impaired or uncorrected hearing&#xD;
&#xD;
          -  Conditions that would interfere with the VR mask placement (e.g. trauma, burn,&#xD;
             infection)&#xD;
&#xD;
          -  Known history of severe motion sickness&#xD;
&#xD;
          -  High blood pressure or symptomatic low blood pressure&#xD;
&#xD;
          -  History of fainting&#xD;
&#xD;
          -  History of angioedema&#xD;
&#xD;
          -  Failed drug test (testing for opiates, cocaine, methamphetamines, amphetamines, and&#xD;
             THC)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luana Colloca, MD/PhD/MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Baltimore School of Nursing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Coordinator</last_name>
    <phone>410-706-5975</phone>
    <email>NRSCollocaLab@umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Massalee, MS</last_name>
    <email>rmassalee@umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Luana Colloca</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luana Colloca, MD,PhD,MS</last_name>
      <phone>301-364-8089</phone>
      <email>Colloca@umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Honzel E, Murthi S, Brawn-Cinani B, Colloca G, Kier C, Varshney A, Colloca L. Virtual reality, music, and pain: developing the premise for an interdisciplinary approach to pain management. Pain. 2019 Sep;160(9):1909-1919. doi: 10.1097/j.pain.0000000000001539. Review.</citation>
    <PMID>30817437</PMID>
  </reference>
  <reference>
    <citation>Colloca L, Raghuraman N, Wang Y, Akintola T, Brawn-Cinani B, Colloca G, Kier C, Varshney A, Murthi S. Virtual reality: physiological and behavioral mechanisms to increase individual pain tolerance limits. Pain. 2020 Sep 1;161(9):2010-2021. doi: 10.1097/j.pain.0000000000001900.</citation>
    <PMID>32345915</PMID>
  </reference>
  <reference>
    <citation>Colloca L. The Placebo Effect in Pain Therapies. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:191-211. doi: 10.1146/annurev-pharmtox-010818-021542. Epub 2018 Sep 14. Review.</citation>
    <PMID>30216744</PMID>
  </reference>
  <reference>
    <citation>Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999 Jan 1;19(1):484-94.</citation>
    <PMID>9870976</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Luana Colloca</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Naloxone</keyword>
  <keyword>Observation</keyword>
  <keyword>TMD volunteers</keyword>
  <keyword>VR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At this time, there is neither intent nor plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

